Iwata H - Search Results

1

Significance of primary lesion resection in Stage IV breast cancer.

Shien T, Iwata H. Shien T, et al. Among authors: iwata h. Jpn J Clin Oncol. 2017 May 1;47(5):381-384. doi: 10.1093/jjco/hyx027. Jpn J Clin Oncol. 2017. PMID: 28334844 Review.

2

[Axillary lymph node dissection in clinically node-positive breast cancer].

Iwata H, Miura S. Iwata H, et al. Nihon Geka Gakkai Zasshi. 2002 Nov;103(11):831-4. Nihon Geka Gakkai Zasshi. 2002. PMID: 12478861 Japanese.

3

Low expression of the snail gene is a good prognostic factor in node-negative invasive ductal carcinomas.

Toyama T, Zhang Z, Iwase H, Yamashita H, Ando Y, Hamaguchi M, Mizutani M, Kondo N, Fujita T, Fujii Y, Iwata H. Toyama T, et al. Among authors: iwata h. Jpn J Clin Oncol. 2006 Jun;36(6):357-63. doi: 10.1093/jjco/hyl038. Epub 2006 Jun 9. Jpn J Clin Oncol. 2006. PMID: 16766568

4

[Effectiveness of breast ultrasound].

Mizutani M, Takada H, Ando Y, Fujita T, Iwata H. Mizutani M, et al. Among authors: iwata h. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:298-303. Nihon Rinsho. 2007. PMID: 17682171 Review. Japanese. No abstract available.

5

[Current situation and features of chemotherapy for breast neoplasms].

Yamashita T, Iwata H. Yamashita T, et al. Among authors: iwata h. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:495-9. Nihon Rinsho. 2007. PMID: 17682200 Review. Japanese. No abstract available.

6

Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.

Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Saji S, et al. Among authors: iwata h. Oncology. 2007;72(5-6):330-7. doi: 10.1159/000113062. Epub 2008 Jan 12. Oncology. 2007. PMID: 18187954 Clinical Trial.

7

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.

Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. Watanabe T, et al. Among authors: iwata h. J Clin Oncol. 2009 Mar 20;27(9):1368-74. doi: 10.1200/JCO.2008.18.3939. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204202 Clinical Trial.

8

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.

Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, Suzuki E. Nakamura S, et al. Among authors: iwata h. Breast Cancer. 2010 Jul;17(3):199-204. doi: 10.1007/s12282-009-0139-3. Epub 2009 Aug 1. Breast Cancer. 2010. PMID: 19649686

9

Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.

Suzuki Y, Tokuda Y, Fujiwara Y, Iwata H, Sasaki Y, Saji S, Aogi K, Nambu Y, Suri A, Saeki T, Takashima S. Suzuki Y, et al. Among authors: iwata h. Jpn J Clin Oncol. 2009 Nov;39(11):699-706. doi: 10.1093/jjco/hyp103. Epub 2009 Sep 22. Jpn J Clin Oncol. 2009. PMID: 19776022 Clinical Trial.

10

Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.

Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H. Yoshimoto N, et al. Among authors: iwata h. Breast Cancer. 2010 Oct;17(4):298-302. doi: 10.1007/s12282-009-0171-3. Epub 2009 Sep 30. Breast Cancer. 2010. PMID: 19789949

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,068 results

Search Page

Filters